In this issue of GOLD, we’re taking a look at the hottest news stories to have emerged during the last 3 months, which are having a profound impact on the pharmaceutical industry. As can be seen below, there have been mergers and collaborations in the pursuit of progress, various executive appointments made, and a concerted effort to tackle global health issues.
Dario Eklund joins Santhera as Chief Executive Officer, having previously served as Chief Commercial Officer at Vifor Pharma.
The Association of the British Pharmaceutical Industry (ABPI) appoints Dr Richard Torbett as its new Chief Executive.
Sanofi announces its acquisition of Synthorx for $2.5 billion to bolster its immune-oncology pipeline.
Roche concludes its acquisition of Spark Therapeutics Inc. following regulatory approval.
Bayer announce their collaboration with UK-based Exscientia to accelerate the potential of AI in cardiovascular and oncology drug discovery.
Eli Lilly announces their agreement to acquire Dermira for $1.1 billion.
Steven Hildemann is named as the new Executive Vice President, Chief Medical Officer of Ipsen.
HIV infections among gay and bisexual men in the UK are reported to have fallen by 71%, following the launch of PrEP, a pill that prevents HIV infection.
The first treatment for thyroid eye disease, Tepezza, receives FDA approval.
Pfizer announces the launch of its Vaccines Division’s Centers of Excellence Network, a global programme of collaborations with academic institutions.
AbbVie’s HIV drug, Kaletra, is repurposed in China as pharma rallies together to combat the coronavirus emergency.
Aimmune Therapeutics drug, Palforzia, becomes the first FDA-approved treatment for peanut allergy.